View Filing Data

Property and Equipment, Net

Note 9. Property and Equipment, Net

		March 31,			December 31,
	Useful Lives	2020			2019
Machinery	3-15 yrs	$	21,088		$	21,088
Furniture and fixtures	3-15 yrs		1,203			1,150
Leasehold improvements	(a)		21,333			21,333
Computer, network equipment and software	3-7 yrs		2,790			2,787
Construction in progress			1,403			1,412
			47,817			47,770
Less: accumulated depreciation and amortization			(38,758	)		(38,044	)
Total property and equipment, net		$	9,059		$	9,726

(a)

Leasehold improvements are amortized over the shorter of the lease term or their estimated useful lives.

Total depreciation and amortization related to property and equipment was $714 and $736 for the three-month periods ended at March 31, 2020 and 2019, respectively.

Right-of-Use Assets and Lease Obligations

3 Months Ended

Mar. 31, 2020

Right-of-Use Assets and Lease Obligations [Abstract]

Right-of-Use Assets and Lease Obligations

Note 10. Right-of-Use Assets and Lease Obligations

The Company leases all realty used as its production and warehouse facilities, corporate headquarters, commercialization operations center and research and laboratory facilities. None of these three leases include the characteristics specified in ASC 842, Leases, that require classification as financing leases and accordingly, these leases are accounted for as operating leases. These leases provide remaining terms between 3.0 years and 6.5 years, including renewal options expected to be exercised to extend the lease periods. Measurement of the operating lease liability reflects an estimated discount rate of 16.9% applied to minimum lease payments, including expected renewals, based on the incremental borrowing rate experienced in the Company’s latest collateralized debt refinancing. For the three months ended March 31, 2020, total operating lease expenses under these leases was $442, including variable lease expenses such as common area maintenance and operating costs totaling $106.

Maturities of the Company’s operating lease liabilities are as follows:

Remainder of 2020	$	910
2021		1,287
2022		1,295
2023		944
2024		565
2025		565
2026		424
Total lease payments		5,990
Less: imputed interest		(1,957	)
Total operating lease liabilities	$	4,033

Intangible Assets, Net and Other Assets

3 Months Ended

Mar. 31, 2020

Intangible Assets, Net and Other Assets [Abstract]

Intangible Assets, Net and Other Assets

Note 11. Intangible Assets, Net and Other Assets

The following table provides the components of identifiable intangible assets, all of which are finite lived, and other assets:

	March 31,			December 31,
	2020			2019
Purchased technology-based intangible	$	2,358		$	2,358
Purchased patent		509			509
		2,867			2,867
Less: accumulated amortization		(2,727	)		(2,714	)
Intangible assets, net		140			153
Other assets, primarily security deposits		288			286
Total Intangible assets, net and other assets	$	428		$	439

Amortization expense was $13 for each of the three-month periods ended March 31, 2020 and 2019, respectively. During the remaining life of the purchased patent, estimated annual amortization expense is $50 for each of the years from 2020 to 2022.

Accounts Payable and Accrued Expenses

3 Months Ended

Mar. 31, 2020

Accounts Payable and Accrued Expenses [Abstract]

Accounts Payable and Accrued Expenses

Note 12. Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following:

	March 31,		December 31,
	2020		2019
Accounts payable	$	10,283	$	12,274
Accrued compensation		1,929		3,758
Real estate and personal property taxes		370		300
Accrued distribution expenses		1,411		1,174
Other		97		243
Total accounts payable and accrued expenses	$	14,090	$	17,749

12.5% Senior Secured Notes and Loans Payable

3 Months Ended

Mar. 31, 2020

12.5% Senior Secured Notes and Loans Payable [Abstract]

12.5% Senior Secured Notes and Loans Payable

Note 13. 12.5% Senior Secured Notes and Loans Payable

12.5% Senior Secured Notes

On July 15, 2019, the Company completed a private placement of up to $100 million aggregate principal of its 12.5% Senior Secured Notes due 2025 (the “Notes”) and issued warrants for two million shares of common stock (the “Warrants”), $.001 par value per share, through the structuring agent, Morgan Stanley & Co., LLC, and entered into a purchase agreement and related agreements including a Collateral Agreement with U.S. Bank National Association, as trustee and collateral agent, and a Lien Subordination and Intercreditor Agreement for the benefit of Madryn Health Partners, other institutional noteholders and U.S. Bank National Association in dual roles providing terms and governing an asset-based loan facility.

Upon closing of the Indenture for such Notes (“Indenture”), the Company issued $70,000 of the principal of the Notes (the “Initial Notes”) along with the Warrants and rights of first offer (the “First Offer Rights”) to the lenders participating in this transaction for Notes and Warrants (the “Lenders”). Issuance of the Initial Notes and Warrants provided net proceeds of $66,082. In addition to the Initial Notes, the Indenture may provide access to further loans of up to $30,000 that may become available in two tranches of Additional Notes tied to the NDA filing for and FDA U.S. marketing approval of Libervant™, an important part of our drug candidate pipeline. Provided that no events of default exist, the Company may elect to, and subject to approval of the holder of a majority of the outstanding principal amount of the Notes, in its discretion, to offer to the Lenders participation in a $10,000 additional offering of 12.5% senior secured notes (the “First Additional Offering”) under terms similar to the Initial Notes, on or before March 31, 2021, upon the filing of the Libervant NDA with the FDA. A second identical funding opportunity would allow the Company to obtain, on or before March 31, 2021, an additional $20,000 if the first option has been elected and funded, or, if not elected or funded, an additional $30,000 may be offered for issuance following FDA approval of Libervant for marketing in the U.S. There can be no assurance that any additional financing will be consummated.

Proceeds from issuance of the Initial Notes and Warrants were used to fully repay the Company’s $56,340 outstanding indebtedness to Perceptive Credit Opportunities Fund, LP (the “Perceptive Loan”), related early repayment fees and legal and other fees incurred to obtain the loan.

The Notes provide a stated fixed rate of 12.5%, payable quarterly in arrears, with the initial quarterly principal repayment of the Initial Notes due on September 30, 2021, and the final quarterly payment due at maturity on June 30, 2025. Principal payments are scheduled to increase annually from 10% of the face amount of debt then outstanding during the first four quarters to 40% of the initial loan principal during the final four quarters.

A debt maturity table is presented below:

Remainder of 2020	$	-
2021		3,500
2022		10,500
2023		17,500
2024		24,500
2025		14,000
Total	$	70,000

The Company may elect, at its option, to prepay the Notes at any time at premiums that range from 101.56% of outstanding principal if prepayment occurs on or after the 5^th anniversary of the issue date of the Notes to 112.5% if payment occurs during the third year after the issuance of the Notes. In the event that redemption occurs within the two years after the issuance of the Notes, a make-whole fee is required, based on the present value of remaining interest payments using an agreed-upon discount rate linked to the then-current U.S. Treasury rate. The Indenture also includes a change of control provision under which the Company may be required to repurchase the Notes at 101% of the remaining principal plus accrued interest at the election of the Lenders.

Collateral for the loan under the Notes consists of a priority lien on substantially all property and assets, including intellectual property, of the Company. This secured obligation provides payment rights that are senior to all existing and future subordinated indebtedness of the Company and provides Lenders with perfected security interests in substantially all of the Company’s assets. In the event that asset-based loans of up to $10,000 (“ABL Facility”) may be obtained, subject receivables and inventory assets will provide a second priority lien to senior secured Noteholders. The Company’s license of its IP to a third-party drug development enterprise (specifically, Sunovion’s APL-130277 product) is one of the various assets serving as collateral for the loan. The Indenture permits the Company to monetize this asset while specifying that a portion of the proceeds, up to $40,000 if the First Additional Offering has not been elected or funded, or, $50,000 if it has been elected and funded, must be applied to prepay the Initial Notes, at 112.5% of the principal amount of the Notes being repurchased, plus accrued and unpaid interest, if any, thereon, to the date of the repurchase, to the extent elected by the Note holders, assuming that such monetization, up to such $40,000 or $50,000 level, as applicable, equals or exceeds those levels and if such monetization does not equal or exceed such level, such prepayment would pro-rated among the Note holders. To the extent that Lenders do not elect repayment of the debt at the date of the monetization, the amount not elected up to $40,000 (or $50,000 if an additional tranche is issued) will be held in a collateral account until approval of Libervant by the FDA for U.S. marketing, at which time this cash collateral is to be released to the Company. Proceeds in excess of $40,000 (or $50,000 if an additional tranche is issued) can be used immediately for general corporate purposes. As of March 31, 2020, the Company was in compliance with all of its covenants.

The Company capitalizes legal and other third-party costs incurred in connection with obtaining debt as deferred debt issuance costs and applies the unamortized portion as a reduction of the outstanding face amount of the related loan in accordance with ASU 2015-03, Interest – Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs. Similarly, the Company amortizes debt discounts, such as those represented by warrants issued to its leaders, and offsets those as a direct reduction of its outstanding debt. Amortization expenses arising from deferred debt issuance costs and debt discounts related to the Notes were $584 for the three months ended March 31, 2020, while comparative amortization expenses derived from deferred debt issuance costs and debt discounts related to the Perceptive Loan for the three months ended March 31, 2019 were $389. Unamortized deferred debt issuance costs and deferred debt discounts total $9,078 and $9,662 as of March 31, 2020 and December 31, 2019, respectively.

Loans Payable - Perceptive

In August 2016, the Company entered into a Loan Agreement and Guaranty with Perceptive Credit Opportunities Fund, LP (“Perceptive”) under which the total available facility of $50,000 had been borrowed as of March 2017. At closing, Perceptive received a warrant to purchase senior common equity interests representing 4.5% of the fully diluted common units of the Company on an as converted basis, which was automatically exercised in full at the time of Aquestive’s IPO. In May 2018, the Company and Perceptive agreed to make certain amendments to the loan agreement then in effect that provided for: (1) the postponement of the initial loan principal payment to May 2019, (2) a delay of the loan maturity date to December 16, 2020 and (3) with Perceptive’s consent, an agreement to permit monetization of the royalties and fees that may be derived from sales of certain apomorphine products and a concurrent agreement for the release of the liens related to these royalties and fees.

In July 2019, the Perceptive Loan was paid in full in connection with the completion of the sale of the 12.5% Notes and Warrants described above. The early extinguishment of this debt resulted in a charge to third quarter 2019 earnings of an amount of $4,896, including an early retirement premium of $2,944 and the remaining balances of the unamortized loan discount and loan acquisition costs.

Warrants Issued to 12.5% Senior Secured Noteholders	3 Months Ended
Warrants Issued to 12.5% Senior Secured Noteholders	Mar. 31, 2020
Warrants Issued to 12.5% Senior Secured Noteholders [Abstract]
Warrants Issued to 12.5% Senior Secured Noteholders	Note 14. Warrants Issued to 12.5% Senior Secured Noteholders The Warrants that were issued in conjunction with the 12.5% Senior Secured Notes (the “Notes”) expire on June 30, 2025 and entitle the holders of the Notes to purchase two million shares of the Company’s common stock at $4.25 per share and include specified registration rights. Management estimated the fair value of the Warrants to be $6,800, assisted by an independent third-party appraiser. The fair value of these Warrants is treated as a debt discount, amortizable over the term of the Warrants, with the unamortized loan portion applied to reduce the face amount of the Notes in the Company’s balance sheet. Additionally, since the Warrants issued do not provide warrant redemption or put rights within the control of the holders that could require the Company to make a payment of cash or other assets to satisfy the obligations under the Warrants, except in the case of a “cash change in control”, the fair value attributed to the Warrants is presented in additional-paid in capital in the accompanying Condensed Consolidated Balance Sheets. Certain holders of the Notes exercised Warrants for the purchase of 428,571 shares of common stock, and proceeds totaling $1,821 were received on December 16, 2019. There were no Warrants exercised by the holders of the Notes during the three-month period ended at March 31, 2020.

Net Loss Per Share

3 Months Ended

Mar. 31, 2020

Net Loss Per Share [Abstract]

Net Loss Per Share

Note 15. Net Loss Per Share

Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares.

As a result of the Company’s net losses incurred for the three-month periods ended at March 31, 2020 and 2019, respectively, all potentially dilutive instruments outstanding would have anti-dilutive effects on per-share calculations for this period. Therefore, basic and diluted net loss per share were the same, as reflected below.

	Three Months Ended at March 31,
	2020			2019
Numerator:
Net loss	$	(16,530	)	$	(14,726	)
Denominator:
Weighted-average number of common shares – basic and diluted		33,569,694			24,963,603
Net loss per common share – basic and diluted	$	(0.49	)	$	(0.59	)

As of March 31, 2020 and 2019, respectively, the Company’s potentially dilutive instruments included 2,947,192, and 1,732,426 options to purchase common shares and 44,036 and 172,655 unvested RSUs that were excluded from the computation of diluted weighted average shares outstanding because these securities had an anti-dilutive impact due to the losses reported. Similarly excluded as of March 31, 2020 were potentially dilutive warrants for the purchase of 1,571,429 common shares. No such dilutive warrants were issued as of March 31, 2019.

Share-Based Compensation

3 Months Ended

Mar. 31, 2020

Share-Based Compensation [Abstract]

Share-Based Compensation

Note 16. Share-Based Compensation

The Company recognized share-based compensation in its Condensed Consolidated Statements of Operations and Comprehensive Loss during 2020 and 2019, respectively, as follows:

	Three Months Ended March 31,
Expense classification:	2020		2019
Manufacture and supply	$	63	$	44
Research and development		182		208
Selling, general and administrative		1,615		1,268
Total share-based compensation expenses	$	1,860	$	1,520

Share-based compensation from:
Restricted stock units	$	464	$	463
Stock options		1,396		1,057
Employee stock purchase plan		—		—
Total share-based compensation expenses	$	1,860	$	1,520

Share-Based Compensation Equity Awards

The following tables provide information about the Company’s restricted stock units and stock option unit activity during the three months ended March 31, 2020:

Restricted Stock Unit Awards (RSUs)

	Number of Units			Weighted Average Grant Date Fair Value Per Share
	(In thousands)
Unvested at December 31, 2019		74		$	14.64
Granted		—			—
Vested		(30	)		15.03
Forfeited		—			—
Unvested at March 31, 2020		44		$	14.38
Grant date fair value of shares vested during the period	$	448
Unrecognized compensation costs at March 31, 2020	$	435

Unrecognized compensation costs related to awards of RSUs are expected to be recognized over a weighted-average period of less than two years.

Stock option awards

	Number of Options		Weighted Average Exercise Price
	(In thousands)
Outstanding at December 31, 2019		2,231	$	10.42
Granted		716	$	1.60
Exercised, Forfeited, Expired		—
Outstanding at March 31, 2020		2,947	$	8.27
Vested or expected to vest at March 31, 2020		2,739	$	8.28
Exercisable at March 31, 2020		666	$	12.75

The weighted average grant date fair value of stock options granted during 2020 was $1.26. The fair value of stock options granted were estimated using the Black-Scholes-Merton pricing model based upon the following assumptions:

	Three Months Ended March 31, 2020
Expected dividend yield	None
Expected volatility		100%
Expected term (years)		6.1
Risk-free interest rate		0.6% - 1.7%

During the three months ended March 31, 2020, options were granted with exercise prices ranging from $1.54 to $4.17, and accordingly, given Aquestive’s share price of $2.19 at the close of the Company’s first quarter of 2020, certain shares granted in 2020 provided intrinsic value of $456 at March 31, 2020.

As of March 31, 2020, $8,693 of total unrecognized compensation expenses related to non-vested stock options is expected to be recognized over a weighted average period of 2.1 years from the date of grant.

Employee stock purchase plan

The Company’s Board of Directors adopted the Aquestive Therapeutics, Inc. Employee Stock Purchase Plan (“ESPP”) in June 2018, as amended and restated effective as of January 1, 2019. Rollout of the ESPP began in late 2018, and initial employee purchases are expected to be made in 2019. The Company may offer common stock purchase rights biannually under offerings that allow for the purchase of common stock at the lower of 85% of the fair value of shares on either the first or last day of the offering period. No purchases under the ESPP occurred in the three months ended March 31, 2020 and 2019, respectively.

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2020
Income Taxes [Abstract]
Income Taxes	Note 17. Income Taxes The Company has accounted for income taxes under the asset and liability method, which requires deferred tax assets and liabilities to be recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts and respective tax bases of existing assets and liabilities, as well as net operating loss carryforwards and research and development credits. Valuation allowances are provided if it is more likely than not that some portion or all of the deferred tax asset will not be realized. The Company has considered the impact of the CARES Act in relation to the 2020 income tax provision, however due to the full valuation allowance and no ability or intent to carryback the 2020 net operating loss, there is no impact. The Company’s tax provision for interim periods is determined using an estimate of its annual effective tax rate, adjusted for discrete items. For the three months ended March 31, 2020 and 2019, the Company recorded no income tax benefit from its pretax losses of $16,530 and $14,726, respectively, due to realization uncertainties. The Company’s U.S. Federal statutory rate is 21%. The primary factor impacting the effective tax rate for the three months ended March 31, 2020 is the anticipated full year operating loss which will require full valuation allowances against any associated net deferred tax assets.

Contingencies

3 Months Ended

Mar. 31, 2020

Contingencies [Abstract]

Contingencies

Note 18. Contingencies

(A) Litigation and Contingencies

From time to time, the Company has been and may again become involved in legal proceedings arising in the ordinary course of business, including product liability, intellectual property, commercial litigation or environmental or other regulatory matters. Except as described below, Aquestive is not presently a party to any litigation or legal proceedings that is believed to be material.

Patent-Related Litigation

Beginning in August 2013, we were informed of abbreviated new drug application (“ANDA”) filings in the United States by Watson Laboratories, Inc. (now Actavis Laboratories, Inc., or “Actavis”), Par Pharmaceutical, Inc. (“Par”), Alvogen Pine Brook, Inc. (“Alvogen”), Teva Pharmaceuticals USA, Inc. (“Teva”), Sandoz Inc. (“Sandoz”), and Mylan Technologies Inc. (“Mylan”), for the approval by the FDA of generic versions of Suboxone Sublingual Film in the United States. We filed patent infringement lawsuits against all six generic companies in the United States District Court for the District of Delaware (the “Delaware District Court”). After the commencement of the ANDA patent litigation against Teva, Dr. Reddy’s Laboratories (“DRL”) acquired the ANDA filings for Teva’s buprenorphine and naloxone sublingual film that are at issue in these trials.

Of these, cases against three of the six generic companies have been resolved.

•

Mylan and Sandoz settled without a trial. Sandoz withdrew all challenges and became the distributor of the authorized generic products.

•

All cases against Par were resolved pursuant to a May 2018 settlement agreement between the Company, Indivior, and Par and certain of its affiliates.

•

Actavis was found to infringe Patent No. 8,603,514, or the ’514 patent, and cannot enter the market until the expiration of the patent in 2024, and the United States Court of Appeals for the Third Circuit (“Federal Circuit”) affirmed that ruling on July 12, 2019.

•

DRL and Alvogen were found not to infringe under a different claim construction analysis, and the Federal Circuit affirmed that ruling on July 12, 2019. Teva has agreed to be bound by all DRL adjudications.

Subsequent to the above, all potential generic competitors without a settlement agreement were also sued for infringement of two additional new patents that contain new claims not adjudicated in the original Delaware District Court case against DRL and Alvogen. On July 12, 2019, the Federal Circuit affirmed the decisions from the previously decided cases. The remaining case against Actavis was dismissed in light of the infringement ruling above, which prevents Actavis from entering the market until 2024. The case(s) against the remaining defendants regarding the additional asserted patents have not been finally resolved. A Markman hearing in the cases against Dr. Reddy’s and Alvogen which is pending in the United States District Court for the District of new Jersey (the “New Jersey District Court”) was held on October 17, 2019. On November 5, 2019, District Judge McNulty of the New Jersey District Court issued a Markman opinion construing the disputed terms of the asserted patents. On January 9, 2020, the New Jersey District Court entered a stipulated order of non-infringement of one of the patents, Patent No. 9,931,305, or the ’305 patent, based on the Federal Circuit’s claim construction ruling, and we and Indivior preserved our rights to appeal the claim construction ruling. On November 19, 2019, Magistrate Judge Waldor of the New Jersey District Court issued an order granting DRL and Alvogen’s requests to file amended answers to add antitrust counterclaims against us and Indivior. We and Indivior appealed the Magistrate Judge’s decision to District Judge McNulty on December 4, 2019, and DRL and Alvogen opposed the appeal. The parties are awaiting further action from the New Jersey District Court on the appeal. On January 17, 2020, we filed a motion to dismiss DRL’s and Alvogen’s antitrust counterclaims for failure to state a claim, and DRL and Alvogen opposed the motion. The parties are awaiting further action from the New Jersey District Court on the motion to dismiss. No trial date has been set in those cases. We are not able to determine or predict the ultimate outcome of this proceeding or provide a reasonable estimate, or range of estimates, of the possible outcomes or loss, if any, in this matter.

On February 19, 2019, the Federal Circuit issued its mandate reversing the New Jersey District Court’s preliminary injunction against Dr. Reddy’s. Following issuance of the mandate, the New Jersey District Court vacated preliminary injunctions against both Dr. Reddy’s and Alvogen. Dr. Reddy’s, Alvogen, and Mylan all launched generic versions of Suboxone Sublingual Film, and the launches by Dr. Reddy’s and Alvogen are “at risk” because the products are the subject of the ongoing patent infringement litigations.

On March 22, 2019, we and Indivior brought suit against Aveva Drug Delivery Systems, Inc., Apotex Corp., and Apotex Inc.in the United States District Court for the Southern District of Florida (the “Southern District of Florida Court”) for infringement of the Company’s U. S. Patent Nos. 8,017,150, 9,687,454, the ’514 patent and ’305 patent, seeking an injunction and potential monetary damages. Following a negotiated settlement between all parties, on December 3, 2019, the parties submitted a Notice of Settlement and a Joint Motion to Approve Consent Judgment. The Southern District of Florida Court entered an order dismissing the suit on December 18, 2019.

We are also seeking to enforce our patent rights in multiple cases against BioDelivery Sciences International, Inc. (“BDSI”). Three cases are currently pending but stayed in the U.S. District Court for the Eastern District of North Carolina (the “Eastern District of North Carolina Court”):

•

The first, a declaratory judgment action brought by BDSI against Indivior and Aquestive, seeks declarations of invalidity and non-infringement of U.S. Patents Nos. 7,897,080, 8,652,378 and 8,475,832. This case is stayed pending final resolution of the above-mentioned appeals on related patents.

•

The second was filed by us and Indivior related to BDSI’s infringing Bunavail product, and alleges infringement of our patent, U.S. Patent No. 8,765,167, or the ’167 patent, and seeks an injunction and potential monetary damages. Shortly after the case was filed, BDSI filed four (4) IPR’s challenging the asserted ’167 patent. On March 24, 2016, the United States Patent Trial and Appeal Board (“PTAB”), issued a final written decision finding that all claims of the ’167 patent were valid. The case was stayed in May 2016 pending the final determination of the appeals on those decisions. Following the PTAB’s February 7, 2019 decisions on remand denying institution, we and Indivior submitted a notice to the Court on February 15, 2019 notifying the Court that the stay should be lifted as a result of the PTAB’s decisions. We are awaiting further action from the Court.

•

On January 13, 2017, we also sued BDSI asserting infringement of the ’167 patent by BDSI’s Belbuca product and seeking an injunction and potential monetary damages. On August 7, 2019, the Eastern District of North Carolina Court granted BDSI’s motion to dismiss the Complaint without prejudice and denied BDSI’s motion to stay as moot. On November 11, 2019, we filed a new Complaint against BDSI in the Eastern District of North Carolina Court. On November 27, 2019, BDSI filed a motion to stay the case pending BDSI’s appeal of the PTAB’s remand decisions, and we opposed the motion. The Eastern District of North Carolina Court denied BDSI’s motion to stay on April 1, 2020. BDSI’s appeal of the PTAB’s remand decisions to the United States Court of Appeals for the Fourth Circuit (the “Federal Fourth Circuit Court”) was docketed on March 13, 2019, and on March 20, 2019, we moved to dismiss the appeal for lack of jurisdiction. On August 29, 2019, the Federal Fourth Circuit Court granted the motion to dismiss BDSI’s appeal. On September 30, 2019, BDSI filed a petition for rehearing in the Federal Fourth Circuit Court en banc, which we opposed. The Federal Fourth Circuit Court denied BDSI’s petition for rehearing en banc on January 13, 2020. After the Federal Fourth Circuit Court denied BDSI’s petition, on January 13, 2020, BDSI filed with the Eastern District of North Carolina Court a motion to dismiss the Complaint, and we opposed on February 2, 2020. The Eastern District of North Carolina Court denied BDSI’s motion to dismiss on April 1, 2020. On April 16, 2020, BDSI filed an Answer to the Complaint, including counterclaims for non-infringement, invalidity, and unenforceability of the ’167 patent. Our response to BDSI’s counterclaims is due May 7, 2020.

Antitrust Litigation

On September 22, 2016, forty-one states and the District of Columbia, or the States, brought suit against Indivior and us in the U.S. District Court for the Eastern District of Pennsylvania, alleging violations of federal and state antitrust statutes and state unfair trade and consumer protection laws relating to Indivior’s launch of Suboxone Sublingual Film in 2010 and seeking an injunction, civil penalties, and disgorgement. After filing the suit, the case was consolidated for pre-trial purposes with the In re Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation, MDL No. 2445, or the Suboxone MDL, a multidistrict litigation relating to putative class actions on behalf of various private plaintiffs against Indivior relating to its launch of Suboxone Sublingual Film. While we were not named as a defendant in the original Suboxone MDL cases, the action brought by the States alleges that we participated in an antitrust conspiracy with Indivior in connection with Indivior’s launch of Suboxone Sublingual Film and engaged in related conduct in violation of federal and state antitrust law. We moved to dismiss the States’ conspiracy claims, but by order dated October 30, 2017, the Court denied our motion to dismiss. We filed an answer denying the States’ claims on November 20, 2017. The fact discovery period closed July 27, 2018, but the parties agreed to conduct certain fact depositions in August 2018. The expert discovery phase closed May 30, 2019, but additional reports and depositions were conducted through August 1, 2019. Daubert briefing is ongoing. The remainder of the case schedule, including summary judgment briefing, is stayed pending resolution of Indivior’s appeal of the District Court’s class certification ruling in a co-pending multi-district litigation to which we are not a party. We are not able to determine or predict the ultimate outcome of this proceeding or provide a reasonable estimate, or range of estimates, of the possible outcome or loss, if any, in this matter.

California Complaint

On December 5, 2019, Neurelis Inc. (“Neurelis”) filed a complaint against Aquestive in the Superior Court of California, County of San Diego alleging Unfair Competition, Defamation, and Malicious Prosecution related to the Company’s pursuit of FDA approval for Libervant™. Neurelis filed a First Amended Complaint on December 9, 2019, alleging the same three causes of action. The Company filed a Motion to Strike Neurelis’s Complaint under California’s anti-SLAPP (“strategic lawsuit against public participation”) statute on Friday, January 31, 2020, which Neurelis is expected to oppose. Neurelis filed a motion for leave to file a Supplemental Complaint on February 5, 2020, which we will oppose. A hearing on our anti-SLAPP motion and Neurelis’s motion for leave was scheduled for April 24, 2020 but was postponed as a result of court closures in San Diego County, California resulting from the COVID-19 pandemic. The parties are awaiting further action from the court regarding a new hearing date. We are not able to determine or predict the ultimate outcome of this proceeding or provide a reasonable estimate, or range of estimates, of the possible outcome or loss, if any, in this matter.

Subsequent Event	3 Months Ended
Subsequent Event	Mar. 31, 2020
Subsequent Event [Abstract]
Subsequent Event	Note 19. Subsequent Event Federal Paycheck Protection Loan On April 17, 2020, the Company was awarded a loan under the federal Paycheck Protection Program (“PPP”) created under the CARES Act in response to the global COVID-19 pandemic. The Company received a $4.8 million loan (the “PPP Loan”) which carried a 1% interest rate payable in 2.5 years. On April 23, 2020, the U.S. Small Business Administration issued revised guidelines which we view as establishing a strong presumption that publicly traded companies are not eligible to receive funding under the PPP. Despite qualifying under the PPP program rules and having been granted the loan, given the revised guidance and the implications of possibly not meeting changing criteria for qualification, we returned our PPP Loan on May 4, 2020.

Basis of Presentation (Policies)	3 Months Ended
Basis of Presentation (Policies)	Mar. 31, 2020
Basis of Presentation [Abstract]
Basis of Presentation	The accompanying interim unaudited condensed consolidated financial statements were prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and with Article 10 of Regulation S-X for interim financial reporting. In compliance with those rules, certain information and footnote disclosures normally included in annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes for the fiscal year ended December 31, 2019 included in our Annual Report on Form 10-K filed with the SEC on March 11, 2020 (the “2019 Annual Report on Form 10-K”). As included herein, the condensed consolidated balance sheet at December 31, 2019 is derived from the audited consolidated financial statements as of that date. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair statement of the results of interim periods have been included. The Company has evaluated subsequent events for disclosure through the date of issuance of the accompanying unaudited condensed financial statements. Any reference in these notes to applicable guidance refers to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).

Summary of Significant Accounting Policies (Policies)	3 Months Ended
Summary of Significant Accounting Policies (Policies)	Mar. 31, 2020
Summary of Significant Accounting Policies [Abstract]
Principles of Consolidation	(A) Principles of Consolidation The interim condensed consolidated financial statements presented herein include the accounts of Aquestive Therapeutics, Inc. and its wholly owned subsidiary, MonoSol Rx, Inc. Other than corporate formation activities, MonoSol Rx, Inc. has conducted no commercial, developmental or operational activities and has no customers or vendors. The results of operations and cash flows reported in these condensed consolidated financial statements should not be regarded as necessarily indicative of results that may be expected in any other interim period or for the entire fiscal year.
Use of Estimates	(B) Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and contingent liabilities, at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to estimates and assumptions include allowances for rebates from proprietary product sales, the allowance for sales returns, the useful lives of fixed assets, valuation of share-based compensation and contingencies.
Recent Accounting Pronouncements	(C) Recent Accounting Pronouncements As an emerging growth company, the Company has elected to take advantage of the extended transition period afforded by the Jumpstart Our Business Startups Act for the implementation of new or revised accounting standards and, as a result, the Company will comply with new or revised accounting standards no later than the relevant dates on which adoption of such standards is required for emerging growth companies. The Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. Recently Adopted Accounting Pronouncements: In February 2016, the Financial Accounting Standards Board issued ASU 2016-02, Leases (Topic 842), and issued amendments in July 2018 provided by ASU 2018-10. This ASU, as amended, requires lessees to recognize lease assets, termed “right-of-use assets” and related lease liabilities on the balance sheet that had previously been classified as operating leases under prior authoritative guidance. For income statement purposes, leases are now required to be classified as either operating or financing leases under a dual model similar to that specified by ASC 840. Operating leases continue to result in straight-line expense while financing leases result in a front-loaded expense pattern in a manner similar to recognition of capital lease expenses under ASC 840. The Company adopted ASU 2016-02 on January 1, 2020 using the modified retrospective transition provisions of ASC 842 to leases in effect as of that date of adoption, and recorded lease liabilities and right-of-use assets, as adjusted for accrued lease payments, in the amount of $4,224 based on an estimated incremental borrowing rate of 16.9%, representing the present value of remaining minimum lease payments. The assets and liabilities thus recorded were primarily those related to the Company’s leased plant, laboratory and corporate administrative facilities. The Company elected to apply the ASU-specified practical expedients and accordingly did not re-assess (i) whether its contracts contained a lease under the new definition of a lease, (ii) the classification of those leases and (iii) initial direct costs of existing leases. In addition, the Company elected not to apply the hindsight expedient in the assessment of lease renewals and resultant term of leases. The Company also elected not to recognize a right-of-use asset and lease liability for those leases with a remaining lease term of 12 months or less. The adoption of ASU 2016-02 did not require a cumulative-effect adjustment to the opening balance of the accumulated deficit at the time of adoption. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, and subsequently amended the standard in ASC 606 which provides a single comprehensive model to be used in accounting for revenue arising from contracts with customers and supersedes previous revenue recognition guidance. The standard’s core principle is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The Company adopted this standard effective January 1, 2019. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, providing guidance on the classification of certain cash receipts and payments in the statement of cash flows intended to reduce diversity in practice, including cash flows related to debt prepayment or extinguishment costs and contingent consideration that may be paid following a business combination. The Company adopted this new guidance on January 1, 2020 without material impact on our condensed consolidated financial position or results of operations. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework. The purpose of the update is to improve the effectiveness of the fair value measurement disclosures that allows for clear communication of information that is most important to the users of financial statements. There were certain required disclosures that have been removed or modified. In addition, the update added the following disclosures: (i) changes in unrealized gains and losses for the period included in other comprehensive income (loss) for recurring Level 3 fair value measurements held at the end of the reporting period and (ii) the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. The Company adopted this new guidance on January 1, 2020 without material impact on our condensed consolidated financial position or results of operations. In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606, which clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer for a promised good or service that is distinct within the collaborative arrangement. The guidance also precludes entities from presenting amounts related to transactions with a collaborative arrangement participant that is not a customer as revenue, unless those transactions are directly related to third-party sales. The Company adopted this new guidance on January 1, 2020 without material impact on our condensed consolidated financial position or results of operations. Recent Accounting Pronouncements Not Adopted as of March 31, 2020: In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326), amending existing guidance on the accounting for credit losses on financial instruments within its scope. The guidance introduces an expected loss model for estimating credit losses, replacing the incurred loss model. The new guidance also changes the impairment model for available-for-sale debt securities, requiring the use of an allowance to record estimated credit losses (and subsequent recoveries). The new guidance is effective for the Company beginning after December 15, 2020. The Company is currently evaluating the impact of the adoption of this guidance on its condensed consolidated financial statements. In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other Internal-Use Software (Subtopic 350-40: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract, which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The update provides guidance distinguishing between capitalizable service contract implementation costs and contract costs required to be expense. In addition, the update requires that the term of the hosting arrangement is to include the non-cancelable period of the arrangement plus periods covered by (i) an option to extend the arrangement if the customer is reasonably certain to exercise that option; (ii) an option to terminate the arrangement if the customer is reasonably certain not to exercise the termination option and (iii) an option to extend (or not to terminate) the arrangement in which exercise of the option is in the control of the vendor. This standard will become effective for the Company beginning January 1, 2021. The amendments may be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. The Company is currently evaluating the impact of ASU 2018-15 on its consolidated financial statements. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740), Simplifying the Accounting for Income Taxes, which amends accounting for income taxes during interim periods and makes changes to certain income tax classifications. The new standard allows exceptions to the use of the incremental approach for intra-period tax allocation, when there is a loss from continuing operations and income or a gain from other items, and to the general methodology for calculating income taxes in an interim period, when a year-to-date loss exceeds the anticipated loss for the year. The standard also requires franchise or similar taxes partially based on income to be reported as income tax and the effects of enacted changes in tax laws or rates to be included in the annual effective tax rate computation from the date of enactment. The standard will be effective for the Company beginning January 1, 2022, with early adoption of the amendments permitted. The Company is currently evaluating the impact from the adoption of ASU 2019-12 on its consolidated financial statements Other pronouncements issued by the FASB or other authoritative accounting standards groups with future effective dates are either not applicable or not significant to the condensed consolidated financial statements of the Company.

Revenues and Trade Receivables, Net (Tables)

3 Months Ended

Mar. 31, 2020

Revenues and Trade Receivables, Net [Abstract]

Revenue

The Company’s revenues were comprised of the following:

	Three Months Ended March 31,
	2020		2019
Manufacture and supply revenue	$	6,916	$	6,669
License and royalty revenue		426		4,622
Co-development and research fees		263		770
Proprietary product sales, net		1,160		582
Total revenues	$	8,765	$	12,643

Disaggregation of Revenue

The following table provides disaggregated net revenue by geographic area:

	Three Months Ended March 31,
	2020		2019
United States	$	7,506	$	12,394
Ex-United States		1,259		249
Total revenues	$	8,765	$	12,643

Trade and Other Receivables, Net

Trade and other receivables, net consist of the following:

	March 31,			December 31,
	2020			2019
Trade receivables	$	8,470		$	9,094
Contract and other receivables		1,406			4,363
Less: allowance for bad debt		(84	)		(124	)
Less: sales-related allowances		(256	)		(203	)
Trade and other receivables, net	$	9,536		$	13,130

Changes in Allowance for Bad Debt

The following table presents the changes in the allowance for bad debt:

	March 31,			December 31,
	2020			2019
Allowance for doubtful accounts at beginning of period	$	124		$	58
(Reversals)/additions charged to bad debt expense		(40	)		66
Recoveries from amounts previously reserved		--			—
Allowance for doubtful accounts at end of period	$	84		$	124

Sales Related Allowances and Accruals

The following table provides a summary of activity with respect to our sales related allowances and accruals for the three months ended March 31, 2020:

	Total Sales Related Allowances and Accruals
Balance at December 31, 2019	$	1,377
Provision related to sales during the period		1,157
Credits and payments		(867	)
Balance at March 31, 2020	$	1,667

Inventories, Net (Tables)

3 Months Ended

Mar. 31, 2020

Inventories, Net [Abstract]

Inventory, net

The components of Inventory, net is as follows:

	March 31,		December 31,
	2020		2019
Raw material	$	1,285	$	1,244
Packaging material		1,101		1,096
Finished goods		701		519
Total inventories, net	$	3,087	$	2,859

Property and Equipment, Net (Tables)

3 Months Ended

Mar. 31, 2020

Property and Equipment, Net

		March 31,			December 31,
	Useful Lives	2020			2019
Machinery	3-15 yrs	$	21,088		$	21,088
Furniture and fixtures	3-15 yrs		1,203			1,150
Leasehold improvements	(a)		21,333			21,333
Computer, network equipment and software	3-7 yrs		2,790			2,787
Construction in progress			1,403			1,412
			47,817			47,770
Less: accumulated depreciation and amortization			(38,758	)		(38,044	)
Total property and equipment, net		$	9,059		$	9,726

(a)

Leasehold improvements are amortized over the shorter of the lease term or their estimated useful lives.

Right-of-Use Assets and Lease Obligations (Tables)

3 Months Ended

Mar. 31, 2020

Right-of-Use Assets and Lease Obligations [Abstract]

Operating Lease Liabilities

Maturities of the Company’s operating lease liabilities are as follows:

Remainder of 2020	$	910
2021		1,287
2022		1,295
2023		944
2024		565
2025		565
2026		424
Total lease payments		5,990
Less: imputed interest		(1,957	)
Total operating lease liabilities	$	4,033

Intangible Assets, Net and Other Assets (Tables)

3 Months Ended

Mar. 31, 2020

Intangible Assets, Net and Other Assets [Abstract]

Components of Identifiable Intangible Assets

The following table provides the components of identifiable intangible assets, all of which are finite lived, and other assets:

	March 31,			December 31,
	2020			2019
Purchased technology-based intangible	$	2,358		$	2,358
Purchased patent		509			509
		2,867			2,867
Less: accumulated amortization		(2,727	)		(2,714	)
Intangible assets, net		140			153
Other assets, primarily security deposits		288			286
Total Intangible assets, net and other assets	$	428		$	439

Accounts Payable and Accrued Expenses (Tables)

3 Months Ended

Mar. 31, 2020

Accounts Payable and Accrued Expenses [Abstract]

Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following:

	March 31,		December 31,
	2020		2019
Accounts payable	$	10,283	$	12,274
Accrued compensation		1,929		3,758
Real estate and personal property taxes		370		300
Accrued distribution expenses		1,411		1,174
Other		97		243
Total accounts payable and accrued expenses	$	14,090	$	17,749

12.5% Senior Secured Notes and Loans Payable (Tables)

3 Months Ended

Mar. 31, 2020

12.5% Senior Secured Notes and Loans Payable [Abstract]

Debt Maturity

A debt maturity table is presented below:

Remainder of 2020	$	-
2021		3,500
2022		10,500
2023		17,500
2024		24,500
2025		14,000
Total	$	70,000

Net Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2020

Net Loss Per Share [Abstract]

Basic and Diluted Net Loss Per Share

	Three Months Ended at March 31,
	2020			2019
Numerator:
Net loss	$	(16,530	)	$	(14,726	)
Denominator:
Weighted-average number of common shares – basic and diluted		33,569,694			24,963,603
Net loss per common share – basic and diluted	$	(0.49	)	$	(0.59	)

Share-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2020

Share-Based Compensation [Abstract]

Share-based Compensation Expense

The Company recognized share-based compensation in its Condensed Consolidated Statements of Operations and Comprehensive Loss during 2020 and 2019, respectively, as follows:

	Three Months Ended March 31,
Expense classification:	2020		2019
Manufacture and supply	$	63	$	44
Research and development		182		208
Selling, general and administrative		1,615		1,268
Total share-based compensation expenses	$	1,860	$	1,520

Share-based compensation from:
Restricted stock units	$	464	$	463
Stock options		1,396		1,057
Employee stock purchase plan		—		—
Total share-based compensation expenses	$	1,860	$	1,520

Restricted Stock Units Awards

Restricted Stock Unit Awards (RSUs)

	Number of Units			Weighted Average Grant Date Fair Value Per Share
	(In thousands)
Unvested at December 31, 2019		74		$	14.64
Granted		—			—
Vested		(30	)		15.03
Forfeited		—			—
Unvested at March 31, 2020		44		$	14.38
Grant date fair value of shares vested during the period	$	448
Unrecognized compensation costs at March 31, 2020	$	435

Stock Option Activity

Stock option awards

	Number of Options		Weighted Average Exercise Price
	(In thousands)
Outstanding at December 31, 2019		2,231	$	10.42
Granted		716	$	1.60
Exercised, Forfeited, Expired		—
Outstanding at March 31, 2020		2,947	$	8.27
Vested or expected to vest at March 31, 2020		2,739	$	8.28
Exercisable at March 31, 2020		666	$	12.75

Valuation Assumptions for Determination of Fair Value of Options

The fair value of stock options granted were estimated using the Black-Scholes-Merton pricing model based upon the following assumptions:

	Three Months Ended March 31, 2020
Expected dividend yield	None
Expected volatility		100%
Expected term (years)		6.1
Risk-free interest rate		0.6% - 1.7%

Corporate Organization and Company Overview (Details) - USD ($) $ in Thousands		1 Months Ended
	Dec. 17, 2019	Dec. 31, 2019
Equity Offering of Common Stock [Abstract]
Number of common shares issued (in shares)	8,050,000	8,050,000
Net proceeds from initial public offering	$ 37,835
Payments for deferred offering costs	2,415
Professional fees and other costs	$ 540

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Mar. 31, 2020
Recent Accounting Pronouncements [Abstract]
Operating lease right of use asset	$ 0	$ 3,912
Lease liabilities		$ 4,033
ASU 2016-02 [Member]
Recent Accounting Pronouncements [Abstract]
Operating lease right of use asset	4,224
Lease liabilities	$ 4,224
Incremental borrowing rate on lease payments	16.90%

Risks and Uncertainties (Details) - USD ($) $ in Thousands		1 Months Ended
Risks and Uncertainties (Details) - USD ($) $ in Thousands	Dec. 17, 2019	Dec. 31, 2019	Jul. 31, 2019	Mar. 31, 2020	Jul. 15, 2019
Risks and Uncertainties [Abstract]
Working capital				$ 35,726
Cash and cash equivalents		$ 49,326		35,521
Debt Instrument, Interest Rate [Abstract]
Accumulated deficit		(130,474)		$ (147,004)
Additional fund amount			$ 52,226
Proceeds from refinancing of debt			$ 13,110
Common Stock issued upon warrant exercises		$ 1,821
Number of common shares issued (in shares)	8,050,000	8,050,000
Net proceeds from initial public offering		$ 37,295
Senior Secured Notes Due 2025 [Member]
Debt Instrument, Interest Rate [Abstract]
Interest rate				12.50%	12.50%
Accumulated deficit				$ (147,004)

Revenues and Trade Receivables, Net, Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Contract with Customer, Asset and Liability [Abstract]
Invoices payable term	105 days
Contract assets	$ 1,458		$ 4,363
Contract liabilities	4,872		$ 5,154
Revenue [Abstract]
Total revenues	$ 8,765	$ 12,643
Minimum [Member]
Contract with Customer, Asset and Liability [Abstract]
Invoices payable term	30 days
Maximum [Member]
Contract with Customer, Asset and Liability [Abstract]
Invoices payable term	60 days
Manufacture and Supply Revenue [Member]
Revenue [Abstract]
Total revenues	$ 6,916	6,669
License and Royalty Revenue [Member]
Revenue [Abstract]
Total revenues	426	4,622
Co-Development and Research Fees [Member]
Revenue [Abstract]
Total revenues	263	770
Proprietary Product Sales, Net [Member]
Revenue [Abstract]
Total revenues	$ 1,160	$ 582

Revenues and Trade Receivables, Net, Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenues by Geographic Market [Abstract]
Total revenues	$ 8,765	$ 12,643
United States [Member]
Revenues by Geographic Market [Abstract]
Total revenues	7,506	12,394
Ex-United States [Member]
Revenues by Geographic Market [Abstract]
Total revenues	$ 1,259	$ 249

Revenues and Trade Receivables, Net, Trade and other receivables, net (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Trade and other receivables, net [Abstract]
Trade receivables	$ 8,470	$ 9,094
Contract and other receivables	1,406	4,363
Less: allowance for bad debt	(84)	(124)	$ (58)
Less: sales-related allowances	(256)	(203)
Trade and other receivables, net	$ 9,536	$ 13,130

Revenues and Trade Receivables, Net, Changes in Allowance for Bad Debt (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Allowance for Doubtful Accounts Receivable [Roll Forward]
Allowance for doubtful accounts at beginning of period	$ 124	$ 58
(Reversals)/additions charged to bad debt expense	(40)	66
Recoveries from amounts previously reserved	0	0
Allowance for doubtful accounts at end of the period	$ 84	$ 124

Revenues and Trade Receivables, Net, Summary of Activity with Sales Related Allowances and Accruals (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Revenues and Trade Receivables, Net [Abstract]
Beginning balance	$ 1,377
Provision related to sales during the period	1,157
Credits and payments	(867)
Ending balance	1,667
Accrued balances - Trade and other receivables, net	256	$ 203
Accrued balances - Accounts payable and accrued expense	$ 1,411	$ 1,174

Revenues and Trade Receivables, Net, Concentration of Major Customers (Details) - Indivior [Member]	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Revenue [Member]
Customer Concentration [Abstract]
Concentrations of risk	79.00%	86.00%
Receivables [Member]
Customer Concentration [Abstract]
Concentrations of risk	63.00%	80.00%

Material Agreements (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		182 Months Ended	189 Months Ended
Material Agreements (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Mar. 31, 2020	Mar. 31, 2019	Feb. 20, 2019	Sep. 30, 2019
Commercial Exploitation Agreement with Indivior [Member]
Agreements [Abstract]
License agreement term		7 years
Automatic renewal period of agreement		1 year
Commercial Exploitation Agreement with Indivior [Member] \| Minimum [Member]
Agreements [Abstract]
Notice period of intent not to renew agreement		1 year
Supplemental Agreement with Indivior [Member]
Agreements [Abstract]
Contingent payments receivable in the future		$ 34,250
Revenues			$ 4,250	$ 40,750
Supplemental Agreement with Indivior [Member] \| Maximum [Member]
Agreements [Abstract]
Contingent payments receivable in the future		75,000
Supplemental Agreement with Indivior Performance or Event-Based Milestones [Member]
Agreements [Abstract]
Contingent payments receivable in the future		33,000
Supplemental Agreement with Indivior Additional Process Patent Rights to the Company [Member]
Agreements [Abstract]
Contingent payments receivable in the future		1,250
License Agreement with Sunovion Pharmaceuticals, Inc. [Member]
Agreements [Abstract]
Revenues		0	0		$ 18,000
License Agreement with Sunovion Pharmaceuticals, Inc Milestones [Member]
Agreements [Abstract]
Revenues					13,000
License Agreement with Sunovion Pharmaceuticals, Inc Milestones [Member] \| Maximum [Member]
Agreements [Abstract]
Contingent payments receivable in the future		45,000
License Agreement with Sunovion Pharmaceuticals, Inc. Upfront [Member]
Agreements [Abstract]
Revenues					$ 5,000
Agreement to Terminate CLA with KemPharm [Member]
Agreements [Abstract]
Revenues	$ 1,000	$ 0	$ 0
Percentage share of milestone payments paid	10.00%

Financial Instruments - Fair Value Measurements (Details) $ in Thousands	Mar. 31, 2020 USD ($)
Level 2 [Member]
Fair Value of Financial Instruments [Abstract]
Assets, fair value	$ 0
Liabilities, fair value	0
Level 3 [Member]
Fair Value of Financial Instruments [Abstract]
Assets, fair value	0
Liabilities, fair value	$ 0

Inventories, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Inventories, Net [Abstract]
Raw material	$ 1,285	$ 1,244
Packaging material	1,101	1,096
Finished goods	701	519
Total inventories, net	$ 3,087	$ 2,859

Property and Equipment, Net (Details) - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Dec. 31, 2019

Less: accumulated depreciation and amortization

$ 47,817

$ 47,770

(38,758)

(38,044)

Total property and equipment, net

9,059

9,726

Property Plant and Equipment Income Statement Disclosures [Abstract]

Depreciation and amortization

714

$ 736

Machinery [Member]

Machinery [Member] | Minimum [Member]

$ 21,088

21,088

Machinery [Member] | Maximum [Member]

3 years

Furniture and Fixtures [Member]

15 years

Furniture and Fixtures [Member] | Minimum [Member]

$ 1,203

1,150

Furniture and Fixtures [Member] | Maximum [Member]

3 years

Leasehold Improvements [Member]

15 years

Computer, Network Equipment and Software [Member]

^[1]

$ 21,333

21,333

Computer, Network Equipment and Software [Member] | Minimum [Member]

$ 2,790

2,787

Computer, Network Equipment and Software [Member] | Maximum [Member]

3 years

Construction in Progress [Member]

7 years